C12Y 207/11024
Mitogen-activated protein kinase , i.e. mapk or mapk2 or c-jun n-terminal kinase
Official title: Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
C12Y207/11024 (Mitogen-activated protein kinase , i.e. mapk or mapk2 or c-jun n-terminal kinase) appears on 40 US grants and 74 published applications in this corpus.
Search patents in C12Y- Granted patents
- 40
- Published applications
- 74
- Assignees
- 50
- Inventors
- 135
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 3 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 3 |
| 2009 | 1 | 2 |
| 2010 | 1 | 3 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 3 |
| 2015 | 3 | 3 |
| 2016 | 1 | 4 |
| 2017 | 3 | 6 |
| 2018 | 3 | 5 |
| 2019 | 4 | 7 |
| 2020 | 3 | 7 |
| 2021 | 3 | 3 |
| 2022 | 5 | 5 |
| 2023 | 1 | 4 |
| 2024 | 2 | 1 |
| 2025 | 0 | 3 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- JNK3 inhibitory peptides4 Aug 2026US 12,698,312 B2Universita' Degli Studi Di Milano
- Methods and compositions for the treatment of epidermolysis bullosa24 Feb 2026US 12,558,316 B2University of Miami
- Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy13 Jan 2026US 12,522,872 B2Dana-Farber Cancer Institute, Inc.
- Methods and compounds for the treatment or prevention of severe influenza19 Nov 2024US 12,145,981 B2Poolbeg Pharma (UK) Limited
- Medicament for liver regeneration and for treatment of liver failure7 May 2024US 11,975,032 B2Medizinische Hochschule Hannover
- Methods and compositions for the treatment of epidermolysis bullosa2 Jul 2026US 2026/0183238 A1University of Miami
- Plants genetically engineered for increased water use efficiency and carbon intake and methods for making and using them19 Mar 2026US 2026/0078398 A1The Regents of the University of California
- Engineering suicide gene approaches to improve chemotherapeutic response in cancer30 Oct 2025US 2025/0332285 A1University of Virginia Patent Foundation
- Modulators of proteasome dynamics and/or function, compositions, methods, and therapeutic uses thereof23 Oct 2025US 2025/0325508 A1Technion Research & Development Foundation Limited
- Methods and compounds for the treatment or prevention of severe influenza9 Jan 2025US 2025/0011400 A1Poolbeg Pharma (UK) Limited
Most cited
By later US patents
- Modified polynucleotides for reducing off-target effects in RNA interference144US 7,595,387 B2Dharmacon, Inc. · 2009
- Modified polynucleotides for reducing off-target effects in RNA interference65US 7,834,171 B2Dharmacon, Inc. · 2010
- Medicament for liver regeneration and for treatment of liver failure25US 9,186,381 B2Helmholtz-Zentrum fuer Infektionsforschung GmbH · 2015
- Antisense modulation of p38 mitogen activated protein kinase expression14US 6,448,079 B1Isis Pharmaceuticals, Inc. · 2002
- Pain treatment using ERK2 inhibitors11US 9,506,068 B2Cornell University · 2016